OKYO Pharma (“OKYO” or the “Company”)

LONDON, 23 Feb. 12, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of new molecules to treat inflammatory dry eye disease and eye pain, has today announced that the patent titled “Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents” has issued from the United States Patent and Trademark Office (“USPTO”) under US Patent Number 11,254,720. This patent contains key claims covering OK-101 for treating neuropathic pain.

OK-101 is OKYO’s preclinical lead compound and a novel long-acting anti-inflammatory drug candidate in development to treat patients with dry eye disease (DED). The drug, intended to be administered topically, is expected to open human studies with a Phase 2 clinical trial in DED patients in the fourth quarter of 2022. OKYO has successfully completed a pre-IND (Investigational New Drug) meeting with the United States Food and Drug Administration (FDA) on February 14and2022, regarding its non-clinical and clinical development plans.

“The pain reduction function of OK-101 offers the possibility that our drug could potentially treat neuropathic corneal pain, a serious, chronic and debilitating condition for which there are currently no approved commercial treatments,” said Raj Patil, PhD, scientific director of OKYO. “We are also excited about the pain relief potential of a dry eye medication, as a significant number of dry eye patients suffer from eye pain. OK-101 may relieve pain in addition to reducing eye inflammation in the millions of DED patients.

“We have made significant progress in our pre-IND work on OK-101 and expect to file the IND to treat DED in Q3/Q4 2022, followed by the start of a Phase 2 trial in DED patients in Q4 2022,” said Dr. Gary S. Jacob, CEO of OKYO. “We believe OK-101 may provide a new way to treat DED patients who are currently not well served by currently approved drugs for the treatment of dry eye disease.”

The person who arranged for the publication of this announcement on behalf of the company was Gary S. Jacob, Ph.D., President and CEO of OKYO.

THIS ANNOUNCEMENT CONTAINS ORIGINAL INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF UK NATIONAL LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EXITING THE EU) REGULATIONS (SI 2019/ 310) (“UK MAR”) . AT THE PUBLISHING OF THIS ANNOUNCEMENT, THIS INITIAL INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Requests:

OKYO Pharma Limited Gary S. Jacob, General Manager

Gabriele Cerrone, Non-Executive Chairman

+44 (0)20 7495 2379
Optiva Securities Limited
(Broker)
Robert Emmet +44 (0)20 3981 4173
Companies RedChip Inc.
(Investor Relations)
David Gentry [email protected]

+1 407-491-4498

Notes for editors:

About OKYO

OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences and biotechnology company admitted to listing on the Standard Segment of the UK Financial Conduct Authority’s official list and to trading on the Main Securities Market. listed on the London Stock Exchange. plc. OKYO focuses on the discovery and development of new molecules to treat inflammatory dry eye disease and neuropathic eye pain.

About OK-101

OK-101 is a lipidated chemerin agonist of the G protein-coupled receptor ChemR23 that is typically found on the immunological cells of the eye responsible for the inflammatory response. OK-101 has previously been shown to produce anti-inflammatory activity in mouse models of DED and is designed to combat washout through the inclusion of the lipid “anchor” within the drug molecule to improve the residence time of OK-101 in the ocular environment. OK-101 has also been shown to exhibit potent ocular pain-reducing properties in a state-of-the-art mouse model of corneal neuropathic pain, establishing its potential to treat both ocular pain and inflammation, two symptoms keys to dry eye, with a single drug.

About dry eye

Dry eye is a multifactorial disease that causes ocular discomfort and tear film instability that can lead to ocular surface damage. It is often a chronic problem, especially in older people, and is expected to become even more prevalent with an aging population and increased use of digital screens such as computers and smart phones. Despite new product approvals, dry eye remains a significant unmet medical need and is a leading cause of patient visits to eye care specialists. New therapies that improve the signs and symptoms of dry eye disease will benefit patients with dry eye disease.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates and projections regarding its industry; his beliefs; and assumptions. Words such as “anticipates”, “expects”, “intends”, “plans”, “believes”, “seeks”, “estimates” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company’s control, are difficult to predict and could cause actual results differ materially from those expressed or anticipated. in forward-looking statements. The Company cautions securityholders and potential securityholders not to place undue reliance on these forward-looking statements, which reflect the Company’s views only as of the date of this announcement. Forward-looking statements made in this announcement relate only to events as of the date the statements are made. The Company undertakes no obligation to publicly release revisions or updates to these forward-looking statements to reflect unforeseen events, circumstances or developments occurring after the date of this announcement, except as required by law or any applicable regulatory authority. ‘required.

For more information, please visit the Company’s website at www.okyopharma.com.

Comments are closed.